A comparison of European and US guidelines for familial hypercholesterolaemia

Current Opinion in Pediatrics

Volumn 26, Issue 3, 2015, Pages 215-220

  Reiner, Zeljko ^a  

^a KBC Zagreb   (Croatia)

Author keywords

coronary heart disease; familial hypercholesterolaemia; guidelines; low density lipoprotein cholesterol; statins

Indexed keywords

ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONSENSUS; DNA DETERMINATION; EUROPE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENE MUTATION; HUMAN; MEDICATION COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; UNITED STATES; CARDIOVASCULAR DISEASES; COMPLICATION; HYPERLIPOPROTEINEMIA TYPE II; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; EARLY DIAGNOSIS; EUROPEAN; MEDICAL SOCIETY;

CARDIOVASCULAR DISEASES; EUROPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84937118490     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000178     Document Type: Review

References (27)

1. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-1818.
2. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (25 Suppl 2):S1-S45.
3. Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014; 35:960-968.
4. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72:171-176.
5. World Health Organization, Human Genetics Programme. Familial hypercholesterolemia: report of a second WHO consultation. WHO/HGN/FH/Cons/99.
6. Geneva: WHO; 1999.
7. Defesche JC, Lansberg PJ, Umans-Eckenhausen MA, Kastelein JJ. Advanced method for the identification of patients with inherited hypercholesterolemia. Semin Vasc Med 2004; 4:59-65.
8. Humphries SE, Whittall RA, Hubbart CS, et al., Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006; 43:943-949.
9. Reiner Z? . Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 2010; 24:19-28.
10. Cannon CP. IMPROVE-IT Trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes [abstract]. In: American Heart Association 2014 Scientific Sessions; 17 November 2014; Chicago, Illinois.
11. Reiner Z. New ESC/EAS guidelines for the management of dyslipidaemias: any controversies behind the consensus? Eur J Cardiovasc Prev Rehabil 2011; 18:724-727.
12. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Europ Heart J 2012; 33:1635-1701.
13. Reiner Z? . Guidelines, position papers and critical reviews: differences and similarities. Eur J Prev Cardiol 2013; 20:3-5.
14. Nordestgaard BG, Chapman MJ, Humphries SE, et al., European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490.
15. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97:3956-3964.
16. Whittall RA, Scartezini M, Li K, et al. Development of a high-resolution melting method for mutation detection in familial hypercholestedrolaemia patients. Ann Clin Biochem 2010; 47:44-55.
17. Peć in I, Whittall R, Futema M, et al. Mutation detection in Croatian patients with familial hypercholesterolemia. Ann Hum Genet 2013; 77:22-30.
18. Cuchel M, Bruckert E, Ginsberg HN, et al., European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35:2146-2157.
19. Reiner Z? . Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis 2013; 23:799-807.
20. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128:S213-S256.
21. ReinerZ? . Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013; 10:453-464.
22. McCrindle BW, Urbina EM, Dennison BA, et al., American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing. Drug therapy of highrisk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115:1948-1967.
23. Kavey RE, Allada V, Daniels SR, et al., American Heart Association Expert Panel on Population and Prevention Science; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism; American Heart Association Council on High Blood Pressure Research; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on the Kidney in Heart Disease; Interdisciplinary Working Group on Quality of Care and Outcomes Research. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006; 114:2710-2738.
24. American Academy of Pediatrics. National Cholesterol Education Program: report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89 (pt 2):525-584.
25. ReinerZ? . Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia. Circ Res 2014; 114:233-235.
26. Descamps OS, Tenoutasse S, Stephenne X, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011; 218:272-280.
27. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol 2014; 8:148-172.